Aclaris Therapeutics (ACRS) Holdings Trimmed by TIAA CREF Investment Management LLC

TIAA CREF Investment Management LLC lessened its position in shares of Aclaris Therapeutics (NASDAQ:ACRS) by 11.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 202,818 shares of the biotechnology company’s stock after selling 27,330 shares during the quarter. TIAA CREF Investment Management LLC’s holdings in Aclaris Therapeutics were worth $5,001,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC acquired a new stake in Aclaris Therapeutics during the 3rd quarter valued at approximately $142,000. Teacher Retirement System of Texas acquired a new stake in Aclaris Therapeutics during the 4th quarter valued at approximately $200,000. Landscape Capital Management L.L.C. acquired a new stake in Aclaris Therapeutics during the 4th quarter valued at approximately $307,000. Caxton Corp increased its position in Aclaris Therapeutics by 76.8% during the 4th quarter. Caxton Corp now owns 17,994 shares of the biotechnology company’s stock valued at $444,000 after purchasing an additional 7,818 shares during the period. Finally, Granite Investment Partners LLC acquired a new stake in Aclaris Therapeutics during the 4th quarter valued at approximately $565,000. 92.19% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

In other Aclaris Therapeutics news, insider Neal Walker purchased 10,000 shares of Aclaris Therapeutics stock in a transaction that occurred on Thursday, April 5th. The stock was acquired at an average price of $16.75 per share, with a total value of $167,500.00. Following the transaction, the insider now owns 897,184 shares in the company, valued at approximately $15,027,832. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Stephen A. Tullman purchased 26,700 shares of Aclaris Therapeutics stock in a transaction that occurred on Friday, April 6th. The stock was acquired at an average cost of $16.54 per share, with a total value of $441,618.00. Following the transaction, the director now owns 157,507 shares in the company, valued at approximately $2,605,165.78. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 37,950 shares of company stock valued at $629,856. Insiders own 16.30% of the company’s stock.

Shares of ACRS stock opened at $17.50 on Thursday. Aclaris Therapeutics has a 52 week low of $16.01 and a 52 week high of $32.65.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.10. The company had revenue of $1.00 million for the quarter, compared to analyst estimates of $0.80 million. equities analysts forecast that Aclaris Therapeutics will post -4.27 earnings per share for the current fiscal year.

Several brokerages have recently commented on ACRS. Guggenheim began coverage on shares of Aclaris Therapeutics in a research report on Thursday, February 8th. They set a “buy” rating and a $53.00 price objective for the company. Zacks Investment Research raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, February 19th. Cantor Fitzgerald set a $50.00 price objective on shares of Aclaris Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 19th. BidaskClub downgraded shares of Aclaris Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Finally, Leerink Swann reduced their price objective on shares of Aclaris Therapeutics from $56.00 to $54.00 and set an “outperform” rating for the company in a research report on Tuesday, March 13th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $43.50.

TRADEMARK VIOLATION WARNING: This story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/19/aclaris-therapeutics-acrs-holdings-trimmed-by-tiaa-cref-investment-management-llc.html.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics (NASDAQ:ACRS).

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply